Leptin is a coactivator of TGF-β in unilateral ureteral obstructive kidney disease

American Journal of Physiology - Renal Physiology

Volumn 293, Issue 4, 2007, Pages

  Kümpers, Philipp ^a   Gueler, Faikah ^a   Rong, Song ^a   Mengel, Michael ^a   Tossidou, Irini ^a   Peters, Imke ^a   Haller, Hermann ^a   Schiffer, Mario ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Inflammation; Obesity; Transforming growth factor ; Tubulointerstitial fibrosis

Indexed keywords

LEPTIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; KIDNEY CELL; KIDNEY FUNCTION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; URETER OBSTRUCTION;

EID: 35348871046     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00003.2007     Document Type: Article

References (47)

1. Benbow U, Brinckerhoff CE. The AP-1 site and MMP gene regulation: what is all the fuss about? Matrix Biol 15: 519-526, 1997.
2. Bottinger EP, Bitzer M. TGF-β signaling in renal disease. J Am Soc Nephrol 13: 2600-2610, 2002.
3. Breyer MD, Bottinger E, Brosius FC, Coffman TM, Fogo A, Harris RC, Heilig CW, Sharma K. Diabetic nephropathy: of mice and men. Adv Chronic Kidney Dis 12: 128-145, 2005.
4. Burns WC, Twigg SM, Forbes JM, Pete J, Tikellis C, Thallas-Bonke V, Thomas MC, Cooper ME, Kantharidis P. Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol 17: 2484-2494, 2006.
5. Chen S, Iglesias-de la Cruz MC, Jim B, Hong SW, Isono M, Ziyadeh FN. Reversibility of established diabetic glomerulopathy by anti-TGF-β antibodies in db/db mice. Biochem Biophys Res Commun 300: 16-22, 2003.
6. +. J Exp Med 198: 1875-1886, 2003.
7. Cheng O, Thuillier R, Sampson E, Schultz G, Ruiz P, Zhang X, Yuen PS, Mannon RB. Connective tissue growth factor is a biomarker and mediator of kidney allograft fibrosis. Am J Transplant 6: 2292-2306, 2006.
8. Cheng S, Pollock AS, Mahimkar R, Olson JL, Lovett DH. Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J 20: 1898-1900, 2006.
9. Chua SC Jr, Chung WK, Wu-Peng XS, Zhang Y, Liu SM, Tartaglia L, Leibel RL. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 271: 994-996, 1996.
10. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 283: F209-F220, 2002.
11. Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, Sanna V, Jebb SA, Perna F, Fontana S, Lechler RI, DePaoli AM, O'Rahilly S. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 110: 1093-1103, 2002.
12. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 395: 763-770, 1998.
13. Fruhbeck G. Intracellular signalling pathways activated by leptin. Biochem J 393: 7-20, 2006.
14. Gunduz Z, Dursun N, Akgun H, Ozturk F, Okur H, Koc N. Renal effects of long-term leptin infusion and preventive role of losartan treatment in rats. Regul Pept 132: 59-66, 2005.
15. Han DC, Isono M, Chen S, Casaretto A, Hong SW, Wolf G, Ziyadeh FN. Leptin stimulates type I collagen production in db/db mesangial cells: glucose uptake and TGF-β type II receptor expression. Kidney Int 59: 1315-1323, 2001.
16. Honda H, Ikejima K, Hirose M, Yoshikawa M, Lang T, Enomoto N, Kitamura T, Takei Y, Sato N. Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology 36: 12-21, 2002.
17. + T cells. J Immunol 173: 6526-6531, 2004.
18. Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ, Lang T, Fukuda T, Yamashina S, Kitamura T, Sato N. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 122: 1399-1410, 2002.
19. Inazaki K, Kanamaru Y, Kojima Y, Sueyoshi N, Okumura K, Kaneko K, Yamashiro Y, Ogawa H, Nakao A. Smad3 deficiency attenuates renal fibrosis, inflammation, and apoptosis after unilateral ureteral obstruction. Kidney Int 66: 597-604, 2004.
20. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med 318: 1657-1666, 1988.
21. Lee CI, Guh JY, Chen HC, Lin KH, Yang YL, Hung WC, Lai YH, Chuang LY. Leptin and connective tissue growth factor in advanced glycation end-product-induced effects in NRK-49F cells. J Cell Biochem 93: 940-950, 2004.
22. Lee FY, Li Y, Yang EK, Yang SQ, Lin HZ, Trush MA, Dannenberg AJ, Diehl AM. Phenotypic abnormalities in macrophages from leptin-deficient, obese mice. Am J Physiol Cell Physiol 276: C386-C394, 1999.
23. Leung JC, Chan LY, Tang SC, Chu KM, Lai KN. Leptin induces TGF-β synthesis through functional leptin receptor expressed by human peritoneal mesothelial cell. Kidney Int 69: 2078-2086, 2006.
24. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 69: 213-217, 2006.
25. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 394: 897-901, 1998.
26. - mice. Am J Pathol 163: 1261-1273, 2003.
27. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1: 1155-1161, 1995.
28. Mancuso P, Huffnagle GB, Olszewski MA, Phipps J, Peters-Golden M. Leptin corrects host defense defects after acute starvation in murine pneumococcal pneumonia. Am J Respir Crit Care Med 173: 212-218, 2006.
29. Matarese G, Di Giacomo A, Sanna V, Lord GM, Howard JK, Di Tuoro A, Bloom SR, Lechler RI, Zappacosta S, Fontana S. Requirement for leptin in the induction and progression of autoimmune encephalomyelitis. J Immunol 166: 5909-5916, 2001.
30. Muller PY, Janovjak H, Miserez AR, Dobbie Z. Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques 32: 1372-1379, 2002.
31. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, Rifkin DB, Sheppard D. The integrin αvβ6 binds and activates latent TGFβ1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96: 319-328, 1999.
32. Oda T, Jung YO, Kim HS, Cai X, Lopez-Guisa JM, Ikeda Y, Eddy AA. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 60: 587-596, 2001.
33. Reeves WB, Andreoli TE. Transforming growth factor β contributes to progressive diabetic nephropathy. Proc Natl Acad Sci USA 97: 7667-7669, 2000.
34. Roestenberg P, van Nieuwenhoven FA, Joles JA, Trischberger C, Martens PP, Oliver N, Aten J, Hoppener JW, Goldschmeding R. Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice. Am J Physiol Renal Physiol 290: F1344-F1354, 2006.
35. Sahai A, Malladi P, Pan X, Paul R, Melin-Aldana H, Green RM, Whitington PF. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 287: G1035-G1043, 2004.
36. Sanchez-Margalet V, Martin-Romero C, Santos-Alvarez J, Goberna R, Najib S, Gonzalez-Yanes C. Role of leptin as an immunomodulator of blood mononuclear cells: mechanisms of action. Clin Exp Immunol 133: 11-19, 2003.
37. Schiffer M, von Gersdorff G, Bitzer M, Susztak K, Bottinger EP. Smad proteins and transforming growth factor-β signaling. Kidney Int Suppl 77: S45-S52, 2000.
38. Susztak K, Sharma K, Schiffer M, McCue P, Ciccone E, Bottinger EP. Genomic strategies for diabetic nephropathy. J Am Soc Nephrol 14: S271-S278, 2003.
39. Tang M, Potter JJ, Mezey E. Leptin enhances the effect of transforming growth factor β in increasing type I collagen formation. Biochem Biophys Res Commun 297: 906-911, 2002.
40. Tang M, Potter JJ, Mezey E. Activation of the human α(I) collagen promoter by leptin is not mediated by transforming growth factor β responsive elements. Biochem Biophys Res Commun 312: 629-633, 2003.
41. Tarzi RM, Cook HT, Jackson I, Pusey CD, Lord GM. Leptin-deficient mice are protected from accelerated nephrotoxic nephritis. Am J Pathol 164: 385-390, 2004.
42. Wolf G, Hamann A, Han DC, Helmchen U, Thaiss F, Ziyadeh FN, Stahl RA. Leptin stimulates proliferation and TGF-β expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. Kidney Int 56: 860-872, 1999.
43. Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 159: 1465-1475, 2001.
44. Yang J, Shultz RW, Mars WM, Wegner RE, Li Y, Dai C, Nejak K, Liu Y. Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest 110: 1525-1538, 2002.
45. Yokoi H, Mukoyama M, Nagae T, Mori K, Suganami T, Sawai K, Yoshioka T, Koshikawa M, Nishida T, Takigawa M, Sugawara A, Nakao K. Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J Am Soc Nephrol 15: 1430-1440, 2004.
46. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425-432, 1994.
47. Ziyadeh FN. Mediators of diabetic renal disease: the case for TGF-β as the major mediator. J Am Soc Nephrol 15, Suppl 1: S55-S57, 2004.